To overcome the biases of input data, Berg LLC's President and CEO Niven Narain asserts, “We start with a hypothesis-agnostic, data-driven model.” All the data are deconstructed down to the very basics, stripped of any assumptions, including around parameterization, for instance (choosing which variables to look at). Then the data are re-constructed again – looking at linkages and correlations, including among different data types.
Put simply, BERG compares diseased and healthy tissue and hones in on the differences to drive new drug discovery. That’s...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?